Study of LW402 in Moderate-to-Severe Atopic Dermatitis
Status:
COMPLETED
Trial end date:
2025-02-13
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.